Pure Biologics S.A. (WSE:PUR)

Market Cap	25.90M +8.3%
Revenue (ttm)	n/a
Net Income	-10.73M
EPS	-1.57
Shares Out	12.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,236
Open	2.170
Previous Close	2.115
Day's Range	2.055 - 2.170
52-Week Range	1.353 - 9.200
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PUR

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error